Coherence Neuro is a technology company.
Coherence Neuro has raised $10.0M across 1 funding round.
Coherence Neuro has raised $10.0M in total across 1 funding round.
Coherence Neuro has raised $10.0M in total across 1 funding round.
Coherence Neuro's investors include Amadeus Capital Partners, Hoxton Ventures, Khosla Ventures, Notion Capital, SciFounders, Sequoia Capital.
Coherence Neuro is a medical technology company developing implantable brain-computer interfaces (BCIs) to manage cancer, particularly gliomas, by monitoring disease progression in real time and delivering targeted bioelectronic stimulation.[1][2][3][4] Their flagship product, SOMA-1 (or SOMA), is a minimally invasive, wireless, coin-sized implant paired with a wearable and app that uses AI to decode electrical signals, personalize therapy, and keep cancer in stasis without the side effects of traditional treatments like chemotherapy or radiation.[1][2][3] The company serves cancer patients, starting with brain tumors, solving the problem of metastatic spread and poor quality of life by transforming cancer into a continuously managed condition at home.[1][3] Founded in 2022 in San Francisco, Coherence raised a $10M seed round and plans clinical entry in 2025, showing strong early momentum through partnerships with Cambridge, Stanford, and Monash.[2][4][5][6]
Coherence Neuro was founded in 2022 in San Francisco by a team of world-leading researchers, engineers, and scientists united by a mission to revolutionize cancer treatment through neurotechnology.[1][5] The idea emerged from recognizing cancer's "electrical language" and the nervous system's role in its progression, quietly building over two years on neural interfaces, AI data pipelines, and bioelectronic therapies.[2] Early traction includes developing human-ready implants like SOMA-1 in collaboration with partners at Cambridge, Stanford, Monash, and Royal Melbourne Hospital, culminating in a $10M seed round in late 2024 or early 2025 to fund clinical trials.[2][4][5][6] This pivotal funding and device readiness mark their shift from R&D to clinic, humanizing their patient-driven, science-fiction-inspired approach.[2][3]
Coherence stands out in neurotechnology and oncology through these key strengths:
Coherence rides the convergence of neurotechnology, AI, and oncology, unlocking "electro-oncology" by treating the body's bioelectric signals as the next therapeutic frontier amid stagnant cancer paradigms of surgery, radiation, and chemo.[1][2][3] Timing is ideal with maturing BCI tech (e.g., implants shrinking to coin-size) and AI's rise in precision medicine, amplified by post-2020 neurotech investments and cancer's global burden.[2][4][6] Market forces like demand for personalized, non-toxic therapies and regulatory paths for minimally invasive devices favor them, while their dataset could accelerate insights into brain-body interactions.[2][3] They influence the ecosystem by inspiring bioelectronic medicine startups and partnering with academia to scale neurotech beyond paralysis to chronic diseases.[1][2]
Coherence is poised to disrupt oncology with SOMA-1's 2025 clinic entry, expanding from gliomas to body-wide applications via its scalable platform.[2][3][5] Trends like AI-driven closed-loop systems, miniaturizing implants, and electroceuticals will propel growth, potentially capturing part of a $100B market as data moats deepen personalization.[2] Their influence may evolve from niche innovator to ecosystem leader, licensing tech or powering pharma partnerships, ultimately proving neurotech can reprogram cancer from within—shifting it from fatal battle to managed reality.[1][3]
Coherence Neuro has raised $10.0M across 1 funding round. Most recently, it raised $10.0M Seed in November 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2025 | $10.0M Seed | Amadeus Capital Partners, Hoxton Ventures, Khosla Ventures, Notion Capital, SciFounders, Sequoia Capital |